Multitarget Ligands in Drug Discovery

Dear Colleagues,

Although single target drugs have shown significant clinical efficacy, most human diseases are not caused by a single gene or target. Some diseases that is harmful to human health, such as cardiovascular and cerebrovascular diseases, diabetes, malignant tumors, Alzheimer's disease, etc., have complex pathogenesis, and most of which are related to multiple genes, and cannot be effectively controlled or cured by using single target drugs. In clinical practice, the combination of single molecular target drugs has been widely used. Multi target drugs have the advantages of combination of single molecular target drugs. They can act on multiple disease-related targets, produce multiple pharmacological activities, and obtain the required diverse biological regulatory functions. At the same time, they can reduce the possible side effects of combination of single target drugs, and achieve the goal of improving the efficacy and safety.

For multi-target ligands in drug discovery, it is important to balance the activity, selectivity and the pharmacokinetic properties, and is still a challenge for pharmaceutical chemists. In order to provide a platform for readers and scientists interested in this research, we planned this special issue. It is my pleasure to invite our colleagues to submit original research manuscripts within the scope of this Special Issue. Short communication and reviews will also be greatly appreciated.

Prof. Dr. Xingshu Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.